Article Abstract

Is it oncologically and clinically safe to adopt a bladder sparing approach in complete responders following neoadjuvant chemotherapy alone without proceeding to a radical cystectomy?

Authors: Ranjan Arianayagam, Anand Sharma, Nikhil Vasdev


Carcinoma of the bladder is the second most common urological cancer and 25% of the cases are muscle invasive in nature (1,2). In order to get better outcomes in patients with muscle invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) based on platinum based regimes is used.